Skip to main content

Table 1 Clinical characteristic of HCC patients and corresponding relationship with CTCs before treatment (n = 21)

From: The clinical significance of CTC enrichment by GPC3-IML and its genetic analysis in hepatocellular carcinoma

Clinical characteristics

Average CTC numbers

Average CTC numbers

Total

EpCam

Vimentin

HSPG

HSPG/total HSPG serial (%)

GPC3

GPC3/total HSPG serial (%)

Age, years

 > 50

8

5

3

2

10.00

3

15.00

 ≤ 50

10

5

5

2

11.11

2

11.11

Gender

 Male

9

5

4

2

10.53

2

10.53

 Female

10

6

3

2

11.11

2

11.11

Number of tumors

 Singleton

9

4

4

2

10.00

3

15.00

 Multiple

9

5

4

2

9.09

4

18.18

AFP

 > 300 ng/mL

12

6

6

2

8.70

3

13.04

 ≤ 300 ng/mL

8

4

3

2

9.52

3

14.29

Tumor size (cm)

 > 5 cm

9

4

4

2

10.00

3

15.00

 ≤ 5 cm

9

5

4

2

10.00

3

15.00

BCLC stage

 0

7

4

3

2

15.38

0

0.00

 A

8

5

3

2

10.00

3

15.00

 B

8

3

5

3

11.11

5

18.52

 C

12

6

6

2

9.09

3

13.64

PIVKA

 > 70 ng/ml

9

5

4

2

9.52

3

14.29

 ≤ 70 ng/ml

8

5

3

3

15.00

4

20.00

Large vessel tumor thrombus

 Yes

12

6

6

2

9.09

3

13.64

 Non

8

4

3

2

9.52

3

14.29

MVI

 = M0

8

5

3

2

10.00

3

15.00

 ≠ M0

9

5

5

2

9.52

3

14.29

  1. HSPG serial of immunoliposomes contain IMLs constructed with antibody of GPC1, GPC3, SDC1, SDC2, and common antibody of HSPG
  2. CTC circulating tumor cell, HSPG heparan sulfate proteoglycans, AFP alpha-fetoprotein, PIVKA protein induced by vitamin K absence, CEA carcinoembryonic antigen
Back to article page

Journal of Nanobiotechnology

ISSN: 1477-3155

Contact us